Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Ononin-modified Chitosan/β-glycerophosphate hydrogel-loaded adipose-derived stem cells promote the repair of diabetic wounds in rats.

Xu F., Peng JC., Li YL., Huang ZX., Teng MJ., Gan CL.

Randomized Controlled Trial on Diabetic Foot, Chronic Wound, published in BMC Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
BMC Biotechnol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41832444
PMCID
PMC13101257
DOI
10.1186/s12896-026-01135-z

Abstract (original English)

OBJECTIVE: To evaluate the mechanistic synergy of an ononin-modified chitosan/β-glycerophosphate (CS/β-GP) hydrogel loaded with adipose-derived stem cells (ADSCs) in repairing diabetic wounds (DWs). We specifically aimed to determine if ononin could biochemically remodel the hostile diabetic microenvironment to enhance ADSCs survival and potency. METHODS: Primary rat ADSCs were characterized by flow cytometry. A thermosensitive CS/β-GP hydrogel was fabricated, and its microstructure was characterized by scanning electron microscopy (SEM). he biological response of ADSCs to ononin was assessed via CCK-8, scratch assays and Live/Dead staining to identify the optimal concentration. A diabetic wound model in rats was established, with all rats randomly assigned into five groups: Control, model, ononin (On), ADSCs, and ononin+ADSCs (On+ADSCs). Wound healing rates were recorded at days 0, 4, 8, and 12 post-treatment. At 12th day, the synergistic impact of ononin and ADSCs on the wound microenvironment was evaluated by measuring healing rates, inflammatory cytokines (TNF-α, IL-1β, IL-6). Additionally, the cumulative release profiles of IGF-1, VEGF, and TGF-β3 from the hydrogel-loaded ADSCs were monitored over 96 h, fitting a Korsmeyer-Peppas kinetic model to characterize the sustained release behavior. Histopathological evaluation, immunohistochemistry for CD31, collagen I, and α-SMA,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsChitosanGlycerophosphatesRatsWound HealingHydrogelsMaleAdipose TissueRats, Sprague-DawleyDiabetes Mellitus, Experimental

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research